Literature DB >> 26392497

Novel Agents against Miltefosine-Unresponsive Leishmania donovani.

Mousumi Das1, Gundappa Saha1, Anil K Saikia2, Vikash Kumar Dubey3.   

Abstract

Visceral leishmaniasis is a deadly endemic disease. Unresponsiveness to the only available oral drug miltefosine poses a big challenge for the chemotherapy of the disease. We report a novel molecule, PS-203 {4-(4,4,8-trimethyl-7-oxo-3-oxabicyclo[3.3.1]non-2-yl)-benzoic acid methyl ester}, as effective against a miltefosine-unresponsive strain of the parasite. Further, combinations of PS-203 with miltefosine were also evaluated and showed promising results against a miltefosine-unresponsive strain.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392497      PMCID: PMC4649250          DOI: 10.1128/AAC.00928-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  A novel synthesis of oxabicyclo[3.3.1]nonanone via (3,5)-oxonium-ene reaction.

Authors:  Pipas Saha; U C Reddy; S Bondalapati; Anil K Saikia
Journal:  Org Lett       Date:  2010-04-16       Impact factor: 6.005

Review 2.  Drug unresponsiveness & combination therapy for kala-azar.

Authors:  T K Jha
Journal:  Indian J Med Res       Date:  2006-03       Impact factor: 2.375

Review 3.  Combination therapy for visceral leishmaniasis.

Authors:  Johan van Griensven; Manica Balasegaram; Filip Meheus; Jorge Alvar; Lutgarde Lynen; Marleen Boelaert
Journal:  Lancet Infect Dis       Date:  2010-03       Impact factor: 25.071

4.  A policy for leishmaniasis with respect to the prevention and control of drug resistance.

Authors:  A Bryceson
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

5.  Carbon nanotube based betulin formulation shows better efficacy against Leishmania parasite.

Authors:  Prakash Saudagar; Vikash Kumar Dubey
Journal:  Parasitol Int       Date:  2014-07-31       Impact factor: 2.230

6.  Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species.

Authors:  Mousumi Das; Prakash Saudagar; Shyam Sundar; Vikash K Dubey
Journal:  FEBS J       Date:  2013-08-23       Impact factor: 5.542

7.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.

Authors:  Karin Seifert; F Javier Pérez-Victoria; Marianne Stettler; María P Sánchez-Cañete; Santiago Castanys; Francisco Gamarro; Simon L Croft
Journal:  Int J Antimicrob Agents       Date:  2007-07-12       Impact factor: 5.283

Review 8.  Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

Authors:  Lucio H Freitas-Junior; Eric Chatelain; Helena Andrade Kim; Jair L Siqueira-Neto
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-01-28       Impact factor: 4.077

9.  Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

Authors:  Karin Seifert; Sangeeta Matu; F Javier Pérez-Victoria; Santiago Castanys; Francisco Gamarro; Simon L Croft
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

10.  Combinations of ascaridole, carvacrol, and caryophyllene oxide against Leishmania.

Authors:  Jacinta Pastor; Marley García; Silvia Steinbauer; William N Setzer; Ramón Scull; Lars Gille; Lianet Monzote
Journal:  Acta Trop       Date:  2015-02-17       Impact factor: 3.112

View more
  2 in total

1.  Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.

Authors:  Prachi Bhalla; Sabera Sultana; Adarsh Kumar Chiranjivi; Anil K Saikia; Vikash Kumar Dubey
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania.

Authors:  Anupriya Baranwal; Adarsh Kumar Chiranjivi; Ashutosh Kumar; Vikash Kumar Dubey; Pranjal Chandra
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.